Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I'm a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris ...

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interim Data from IIS Study Shows 75% Response Rate and Three ...

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Soligenix (SNGX) announced interim results from the ongoing open-label, investigator-initiated study evaluating extended HyBryte treatment for ...

Tumors develop when cells in the body grow uncontrollably ... They are known as “silent killers” because dogs don’t always ...